Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 38 clinical trials
Management of Progressive Disease in Idiopathic Pulmonary Fibrosis (PROGRESSION)

-modifying therapies, pirfenidone and nintedanib, have been approved worldwide. Both drugs reduce the disease progression as measured by progressive decline in forced vital capacity (FVC), with a reduction

  • 23 views
  • 24 Mar, 2022
  • 5 locations
Pectoralis and Serratus Muscle Blocks

The overall research plan is PECS/SAP blocks with liposomal bupivacaine improve the Overall Benefit Analgesia Score averaged over the postoperative days 1, 2, and 3. A 2-point reduction in OBAS will be considered the minimal clinically important benefit.

  • 0 views
  • 26 Mar, 2022
  • 1 location
Nebulised Liposomal Amphotericin for Invasive Pulmonary Aspergillosis (NAIFI01 Study) (NAIFI01)

The investigators aim to assess the safety and efficacy of nebulized liposomal amphotericin B (ALN) as a complementary therapy to the usual systemic treatment in patients with invasive pulmonary aspergillosis and the utility of a non-routine test as a surrogate marker of efficacy. To this end, a 3-year phase I, …

  • 38 views
  • 27 Feb, 2022
  • 1 location
Cardiovascular Effects of Exposure to Wood Smoke in Healthy Human Adults (MASKOFF)

Purpose: The study is designed to investigate cardiovascular effects of young healthy human subjects exposed to wood smoke. Participants: Approximately 80 young (18-35 years old) healthy subjects to complete. Procedure (methods): After consenting to participate in the study, subjects will undergo exposures over consecutive days, once to filtered air alone …

Accepts healthy volunteers
  • 41 views
  • 28 Feb, 2022
  • 1 location
Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD

The ILDnose study a multinational, multicenter, prospective, longitudinal study in outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as diagnostic tool for diagnosis and differentiation between the most prevalent fibrotic interstitial lung diseases. The value of eNose as biomarker for disease progression and response …

  • 0 views
  • 29 Jan, 2021
  • 4 locations
Digital Prevention of Asthma (AsthmaTuner)

Asthma self-management is dependent on support and education. To facilitate self-management have we developed and CE-mark a novel digital self-management system called Asthmatuner (Medituner AB, Sweden).The primary aim of this program is to evaluate if self-management with Asthmatuner improves asthma control more than traditional self-management. RCT with two arms, Asthmatuner …

pulmonary function test
  • 4 views
  • 24 Feb, 2022
  • 1 location
Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19

patients who have pulmonary fibrotic changes after suffering severe COVID19 pneumonia, analysed by % change in forced vital capacity (FVC) % fibrosis in high resolution computed

  • 11 views
  • 09 Jan, 2022
  • 3 locations
Breathing Room Intervention to Achieve Better Lung Health in Older Adults

of this pilot is to examine the effect of Breathing Room on inspiratory muscle strength, spirometry confirmed ventilatory function (Forced Expiratory Volume in one second (FEV1), Forced Vital

Accepts healthy volunteers
  • 0 views
  • 29 Apr, 2022
Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease

face to face or via telephone and will be assessed to collect data for study objectives such as ALSFRS-R, Forced Vital Capacity, pain and spasticity score, and quality of life. Thirty (30) participants

amyotrophic lateral sclerosis
primary lateral sclerosis
cannabinoids
spasticity
motor neuron disease
  • 57 views
  • 05 Mar, 2022
  • 1 location
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial (PRECISIONS)

fibrosis (IPF) who have the TOLLIP rs3750920 TT genotype. The study will compare the time to a composite endpoint of relative decline in lung function [10% relative decline in forced vital capacity (FVC

nintedanib
acetylcysteine
pirfenidone
forced vital capacity
  • 0 views
  • 24 Mar, 2022
  • 16 locations